FRONTEO signs exclusive negotiation agreement with Sumitomo Dainippon Pharma for schizophrenia diagnosis support AI program

2021.08.12 Press release

--To the press -

FRONTEO signs exclusive negotiation agreement with Sumitomo Dainippon Pharma for schizophrenia diagnosis support AI program

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Mothers)

 FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) is working with Sumitomo Dainippon Pharma Co., Ltd. (Headquarters: Osaka City, Osaka Prefecture, President: Hiroshi Nomura) and artificial intelligence " We have signed an exclusive negotiation agreement for the research and development of an AI program that supports the diagnosis of schizophrenia using "Concept Encoder (trademark: conceptencoder, reading: concept encoder, hereinafter referred to as artificial intelligence)".

 

 The number of patients with schizophrenia in Japan is estimated to be about 80, and it is estimated that 0.7% of the total population (a little less than 100 in 1) is affected worldwide.1), It is said that there are many cases of onset from adolescence to adolescence2)..As the condition of this disease progresses, it often becomes difficult to continue social life, and while early diagnosis and treatment are important, there are issues such as the need for specialized knowledge and experience for diagnosis and the shortage of specialists. It has become. FRONTEO hopes to help solve these problems by developing a diagnostic support AI program that uses the artificial intelligence.

 

 FRONTEO is proceeding with clinical development of a dementia diagnosis support AI program using the artificial intelligence, and has been conducting clinical trials for approval application since April 2021.We are also developing a diagnostic support AI program for other diseases by making use of the knowledge we have accumulated so far regarding clinical development and commercial development. FRONTEO will continue to improve the quality of medical care and the QOL of patients through the research and development of diagnostic support AI programs.

 

 The impact of this matter alone on FRONTEO's business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

 

1) Ministry of Health, Labor and Welfare: Schizophrenia, Let's start by knowing everyone's mental health comprehensive site,
  https://www.mhlw.go.jp/kokoro/know/disease_into.html/
2) Ministry of Health, Labor and Welfare: Schizophrenia, e-Health Net,
  https://www.e-healthnet.mhlw.go.jp/information/dictionary/heart/yk-071.html

 


■ About Concept Encoder

URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■ About conversational dementia diagnosis support AI program
URL:https://lifescience.fronteo.com/aidevice/dementia/
The conversational dementia diagnosis support AI program uses FRONTEO's original natural language analysis AI "Concept Encoder" to screen cognitive dysfunction from daily conversation between patients and doctors for about 5 to 10 minutes. is. FRONTEO believes that this device can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which is facing a super-aging society. I am. FRONTEO entered into a business alliance agreement with Kyowa Pharmaceutical Industry Co., Ltd., which aims to become a CNS (central nervous system) total solution company, in June 2020, aiming for early commercialization and early market penetration in the medical field.Patent registration number: Patent No. 6

■ About Sumitomo Dainippon Pharma URL:https://www.ds-pharma.co.jp/
Sumitomo Dainippon Pharma's corporate philosophy is to "contribute widely to society by creating new value based on research and development for people's healthy and prosperous lives."
We are making every effort to research and develop new drugs in order to realize this philosophy and to deliver innovative and useful drugs to people in Japan and around the world.Sumitomo Dainippon Pharma aims to create innovative pharmaceuticals by focusing on the neuropsychiatric, oncology, and regenerative / cell medicine fields, which have high unmet medical needs.We are also working to provide new value that can contribute to the realization of "diversified health" in areas other than pharmaceuticals.Focusing on prevention and patient care in addition to disease treatment, we are aiming to commercialize by building a business foundation centered on areas where synergies can be expected with our own pharmaceutical business.

■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge" , Drug discovery support, dementia diagnosis support, financial / human resources / sales support, etc., contributing to solving various corporate issues. Listed on TSE Mothers on June 2014, 2007. January 6 Obtained a first-class medical device manufacturing and sales license (permit number: 26B2021X1).The capital is 13 thousand yen (as of March 1, 10350).

* FRONTEO, Coroban, conceptencoder, and KIBIT are registered trademarks of FRONTEO in Japan.

<Contact information for the press>

Public Relations Officer, FRONTEO Inc. Segawa

Email: pr_contact@fronteo.com

 

<Inquiries about Life Science AI Business>

FRONTEO Inc. Life Science AI Business Headquarters

https://lifescience.fronteo.com/contact

ja 日本語
Machine Translation by Google. : close x